转移性甲状腺髓样癌原发灶切除的生存结局与最佳候选患者
基于监测、流行病学和最终结果数据库2010至2020年186例初诊转移性甲状腺髓样癌患者,评估器官特异性转移及转移器官数量的预后意义,并分析原发灶切除的治疗价值。原发灶切除组总体死亡率和癌症特异性死亡率降低,在骨、肺、肝或远处淋巴结转移及1或2个转移器官患者中生存获益显著。
要点
- 脑转移患者总体生存(P=.007)和癌症特异性生存(P=.0013)显著更差。
- 105例(56.45%)接受原发灶切除,该组总体死亡率和癌症特异性死亡率均降低(均P<.05)。
- 骨、肺、肝或远处淋巴结转移及1或2个转移器官者,原发灶切除与更好生存显著相关(均P<.05)。
核心结论
- 原发灶切除可能为经过仔细选择的转移性甲状腺髓样癌患者带来治疗获益。
- 作者认为未来需开展多中心前瞻性研究以将这些见解整合进临床决策。
研究设计与样本
- 研究基于监测、流行病学和最终结果数据库,纳入2010至2020年初诊转移性甲状腺髓样癌患者186例。
- 采用单变量和多变量Cox比例风险回归模型识别生存预测因素,Kaplan-Meier法计算生存结局,log-rank检验进行比较。
主要发现
- 骨、肺和肝是最常见转移器官。
- 脑转移患者总体生存显著更差(P=.007),癌症特异性生存显著更差(P=.0013)。
- 105例(56.45%)接受原发灶切除,该组总体死亡率和癌症特异性死亡率均降低(均P<.05)。
- 骨、肺、肝或远处淋巴结转移患者中,原发灶切除显著降低总体死亡风险和癌症特异性死亡风险(均P<.05)。
- 1或2个转移器官患者中,手术切除与更好的总体生存显著相关(P=.008)和癌症特异性生存显著相关(P=.0247)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Medullary thyroid cancer (MTC) often exhibits aggressive growth with distant organ metastasis, leading to poor survival. OBJECTIVE: The question of whether primary tumor resection (PTR) is beneficial for patients with metastatic MTC remains a subject of debate. In this study, we evaluated the prognostic significance of organ-specific metastases and the number of metastatic organs in these patients, and we also conducted an analysis to determine the therapeutic value of PTR in managing this rare malignancy. MATERIALS AND METHODS: Patients initially diagnosed with metastatic MTC were identified within the Surveillance, Epidemiology, and End Results database. Univariable and multivariable Cox proportional hazards regression models were performed to identify survival predictors. Survival outcomes were calculated using the Kaplan-Meier method and compared using the log-rank tests. RESULTS: A total of 186 patients with metastatic MTC at initial diagnosis from 2010 to 2020 were included. Bone, lung, and liver were the most common metastatic organs. Patients with brain metastasis had significantly worse overall survival (P = .007) and cancer-specific survival (P = .0013). Among all patients, 105 (56.45%) underwent PTR, and this group showed reduced overall mortality and cancer-specific mortality (all P < .05). When analyzing different metastatic patterns, PTR significantly lowered the risk of overall mortality and cancer-specific mortality for patients with bone, lung, liver, or distant lymph node involvement (all P < .05). Additionally, among patients with 1 or 2 metastases, those undergoing surgical resection were significantly associated with favorable overall survival (P = .008) and cancer-specific survival (P = .0247). CONCLUSION: PTR may confer therapeutic benefits for carefully selected individuals with metastatic MTCs. To integrate these insights into clinical decision-making settings, it is imperative to undertake multicenter prospective studies in the future.
引用
- Liu CQ, Shen CK, Du YX, et al. Survival Outcome and Optimal Candidates of Primary Tumor Resection for Patients With Metastatic Medullary Thyroid Cancer. J Clin Endocrinol Metab. 2024. PMID: 38570918. doi:10.1210/clinem/dgae214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。